Skip to main content
Nirvana Life Sciences Inc logo

Nirvana Life Sciences Inc — Investor Relations & Filings

Ticker · NIRV CSE Professional, scientific and technical activities
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-09-08 Interim / Quarterly Rep…
Country CA Canada
Listing CSE NIRV

About Nirvana Life Sciences Inc

https://nirvanalifescience.com/

Nirvana Life Sciences Inc. is a scientific research and development company focused on creating novel therapeutic products derived from psychedelics, primarily psilocybin. The company's core mission is twofold: to develop non-addictive medicines capable of breaking human addiction to opioids, and to create non-addictive pain relief alternatives to replace opioid medications. Utilizing proprietary formulations and extraction technologies, Nirvana is conducting pre-clinical trials to validate the efficacy of its psilocybin-based compounds for addiction treatment, chronic pain management, anxiety, and depression. The company aims to provide effective, non-addictive solutions to address the global opioid crisis.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Nirvana Life Sciences Inc. for the three months ended July 31, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Equity, Statement of Cash Flows) and detailed notes to the financial statements. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. Q2 2025
2025-09-08 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a NI 52-109 Form 52-109FV1 “Certification of annual filings – venture issuer basic certificate” executed by the CFO, which is a regulatory certification form rather than the full annual report or an audit opinion. It does not present financial statements or audit results, nor does it announce a report; it is a standalone regulatory filing with no fitting category other than the general regulatory filings fallback. Therefore it is classified as RNS.
2025-09-08 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a NI 52-109 Form 52-109FV1 Certification (venture issuer basic certificate) signed by the CEO certifying the annual filings (AIF, financial statements, MD&A) for the year ended April 30, 2025. It is not the annual report itself nor an announcement of release; it is a regulatory compliance certificate filed under Canadian securities rules. This falls under the general "Regulatory Filings" fallback category (RNS).
2025-09-08 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a completed OSC Form 13-502F1 participation fee submission to the Ontario Securities Commission. It is a regulatory form/certification rather than a financial report or announcement like an annual report, interim report, earnings release, etc. This fits the fallback category for miscellaneous regulatory filings.
2025-09-08 English
Annual MD&A - English.pdf
Management Reports Classification · 1% confidence The document is a detailed Management Discussion and Analysis (MD&A) pursuant to Form 51-102F1 for the year ended April 30, 2025. It provides management’s discussion of results, business overview, liquidity, capital resources, related party transactions, quarterly and annual financial analyses. This aligns exactly with the definition of a Management Reports (MDA) filing.
2025-09-08 English
Audited annual financial statements – English.pdf
Annual Report Classification · 1% confidence The document is a comprehensive set of 'Consolidated Financial Statements' for Nirvana Life Sciences Inc. for the years ended April 30, 2025 and 2024. It includes an Independent Auditor's Report, Consolidated Statements of Financial Position, Statements of Loss and Comprehensive Loss, Statements of Changes in Deficiency, and Statements of Cash Flows. This constitutes a full annual financial report, which falls under the '10-K' (Annual Report) category in the provided schema. FY 2025
2025-09-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.